Testing Diabetes Drug for Fatty Liver Disease
Part of Digestive system clinical trials.
This trial tests a diabetes medication (SGLT2 inhibitor) to see if it can help treat non-alcoholic fatty liver disease. If you have fatty liver not caused by alcohol, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You should not drink alcohol regularly.
- You cannot have other liver diseases like hepatitis or autoimmune conditions.
- Your kidney function must be normal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether SGLT2 inhibitors, a type of diabetes medication, can help reduce fat buildup in the liver (NAFLD) for people with type 2 diabetes who also have moderate kidney problems (stage 3 or 4 CKD). It may offer a new way to treat both conditions together.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This trial studies whether an SGLT2 medicine can improve non-alcoholic fatty liver disease (fatty liver not caused by alcohol) in teens with obesity. It may help lower liver fat or liver irritation, alongside usual lifestyle changes.
This trial studies whether erugliflozin can reduce liver fat and liver scarring (fibrosis) while also improving blood sugar in people with type 2 diabetes and fatty liver disease (NASH/NAFLD). It’s designed for people who haven’t used certain diabetes medicines like SGLT2 inhibitors or insulin before.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
Hear when a new Non Alcholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.